EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden

Giuseppe Mario Bentivenga, Angela Mammana, Simone Baiardi, Marcello Rossi, Alice Ticca, Franco Magliocchetti, Andrea Mastrangelo, Anna Poleggi, Anna Ladogana, Sabina Capellari, Piero Parchi iD

Acta Neuropathologica · 2024-06 · 147 (1)

DOI: 10.1007/s00401-023-02663-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 19.01.2024. Verfasst von Giuseppe Mario Bentivenga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Lewy Body Disease, Creutzfeldt-Jakob Syndrome. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Ministero dell'Università e della Ricerca, Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of in vitro seed amplification assays (SAA) detecting misfolded alpha-synuclein (αSyn) in cerebrospinal fluid (CSF) and other tissues has provided a pathology-specific biomarker for Lewy body disease (LBD). However, αSyn SAA diagnostic performance in early pathological stages or low Lewy body (LB) pathology load has only been assessed in small cohorts. Moreover, the relationship between SAA kinetic parameters, the number of αSyn brain seeds and the LB pathology burden assessed by immunohistochemistry has never been systematically investigated. We tested 269 antemortem CSF samples and 138 serially diluted brain homogenates from patients with and without neuropathological evidence of LBD in different stages by the αSyn Real-Time Quaking-Induced Conversion (RT-QuIC) SAA. Moreover, we looked for LB pathology by αSyn immunohistochemistry in a consecutive series of 604 Creutzfeldt–Jakob disease (CJD)-affected brains. αSyn CSF RT-QuIC showed 100% sensitivity in detecting LBD in limbic and neocortical stages. The assay sensitivity was significantly lower in patients in early stages (37.5% in Braak 1 and 2, 73.3% in Braak 3) or with focal pathology (50% in amygdala-predominant). The average number of CSF RT-QuIC positive replicates significantly correlated with LBD stage. Brain homogenate RT-QuIC showed higher sensitivity than immunohistochemistry for the detection of misfolded αSyn. In the latter, the kinetic parameter lag phase (time to reach the positive threshold) strongly correlated with the αSyn seed concentration in serial dilution experiments. Finally, incidental LBD prevalence was 8% in the CJD cohort. The present results indicate that (a) CSF RT-QuIC has high specificity and sufficient sensitivity to detect all patients with LB pathology at Braak stages > 3 and most of those at stage 3; (b) brain deposition of misfolded αSyn precedes the formation of LB and Lewy neurites; (c) αSyn SAA provides “quantitative” information regarding the LB pathology burden, with the lag phase and the number of positive replicates being the most promising variables to be used in the clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lewy Body DiseaseCreutzfeldt-Jakob SyndromeHumansalpha-SynucleinSensitivity and SpecificityBrain

Stichwörter der Autor:innen

AmygdalaDiagnosisLewy bodiesParkinson’s diseaseRT-QuICα-Synuclein

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Department of Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
  • Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. piero.parchi@unibo.it.
  • IRCCS, Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy. piero.parchi@unibo.it.

ORCID-Profile: Piero Parchi

Förderung

  • Ministero della Salute
  • Ministero dell'Università e della Ricerca
  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Bentivenga, G. M., Mammana, A., Baiardi, S., Rossi, M., Ticca, A., Magliocchetti, F., Mastrangelo, A., Poleggi, A., Ladogana, A., Capellari, S., & Parchi, P. (2024). Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-023-02663-0

Vancouver

Bentivenga GM, Mammana A, Baiardi S, Rossi M, Ticca A, Magliocchetti F, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathologica. 2024;147(1). doi:10.1007/s00401-023-02663-0

BibTeX
@article{Bentivenga2024,
  author = {Bentivenga, Giuseppe Mario and Mammana, Angela and Baiardi, Simone and Rossi, Marcello and Ticca, Alice and Magliocchetti, Franco and Mastrangelo, Andrea and Poleggi, Anna and Ladogana, Anna and Capellari, Sabina and Parchi, Piero},
  title = {Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden},
  journal = {Acta Neuropathologica},
  year = {2024},
  volume = {147},
  number = {1},
  doi = {10.1007/s00401-023-02663-0}
}
Kostenlos starten →